Results 21 to 30 of about 13,138 (168)
Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia
Biomedical and Biotechnology Research Journal, 2020 Background: Dyslipidemia (DL) is a blood lipid disorder characterized by high cholesterol, triglyceride and low density lipoprotein with reduction of high density lipoprotein.
Huda A Rasheed +4 more
doaj +1 more source
Biology, 2014 Lipoprotein subclass concentrations are modifiable markers of cardiovascular disease risk. Fenofibrate is known to show beneficial effects on lipoprotein subclasses, but little is known about the role of genetics in mediating the responses of lipoprotein
Alexis C. Frazier-Wood +9 more
doaj +1 more source
BMC Ophthalmology, 2018 Background Previous studies suggested that use of fenofibrate could significantly reduce the rate of progression into diabetic retinopathy (DR), and that retinal nerve fiber layer (RNFL) loss, which has been considered an important indicator for retinal ...
Rui Shi, Lei Zhao, Yun Qi
doaj +1 more source
Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats
Journal of Lipid Research, 2002 The level of maternal circulating triglycerides during late pregnancy has been correlated to newborns' weight in humans. To investigate the response to fenofibrate, a hypotriglyceridemic agent, in pregnant rats, 0, 100, or 200 mg of fenofibrate/kg body ...
Ana Soria, Carlos Bocos, Emilio Herrera
doaj +1 more source
Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review [PDF]
Diabetes & Metabolism JournalHypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk.
Chaicharn Deerochanawong +2 more
doaj +1 more source
EBioMedicine, 2016 Neovascular eye diseases including retinopathy of prematurity, diabetic retinopathy and age-related-macular-degeneration are major causes of blindness.
Yan Gong +14 more
doaj +1 more source
Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2. [PDF]
PLoS ONE, 2013 The orphan nuclear receptor, small heterodimer partner (SHP), appears to play a negative regulatory role in innate immune signaling. Emerging evidence warrants further study on the therapeutic targeting of SHP to suppress excessive and deleterious ...
Chul-Su Yang +8 more
doaj +1 more source
Nutrition & Diabetes, 2023 Background Fenofibrate is a hypolipidemic peroxisome proliferator-activated receptor α (PPARα) agonist used clinically to reduce hypercholesterolemia and hypertriglyceridemia. Objective We investigated the effects of fenofibrate on insulin resistance and
Jungu Lee +3 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed +7 more
wiley +1 more source
Scientific ReportsDiabetic corneal neuropathy (DCN) is a common diabetic ocular complication with limited treatment options. In this study, we investigated the effects of topical and oral fenofibrate, a peroxisome proliferator-activated receptor-α agonist, on the ...
Hassan Mansoor +10 more
doaj +1 more source